Skip to main content

Significant Pharmaceuticals Reported in US Patents

  • 1st Edition - May 2, 2007
  • Latest edition
  • Author: Thomas F. DeRosa
  • Language: English

Significant Pharmaceuticals Reported in US Patents identifies the next generation of pharmaceuticals reported in US Patents. This "hands-on" title provides explicit laborator… Read more

Description

Significant Pharmaceuticals Reported in US Patents identifies the next generation of pharmaceuticals reported in US Patents. This "hands-on" title provides explicit laboratory methods for preparing the most recent and effective medications. Each entry documents the biological testing protocols used to evaluate a drug and the significance of the current treatment agent over previous methods. Pharmaceuticals are included in this review only if at least two of the following criteria were met: Effectiveness in treating an illness, Innovative, ease of preparation, synergy with existing Medications.

Pharmaceuticals are reported for 27 separate classes of illness, including: AIDS, Alzheimer's Disease, Cardiovascular Disorders, Diabetes, Epilepsy, Hepatitis C, Osteoporosis, Obesity and Sleep Disorders.

Significant Pharmaceuticals Reported in US Patents has been designed to be used as both a reference and synthetic guide for pharmaceutical, medicinal and organic chemists and graduate students.

Researchers working in other areas will also find the information valuable as in many instances intermediates or the next generation pharmaceutical are readily convertible into other industrial products including: anti-oxidants, chemical additives, herbicides, polymer precursors, water purification agents. Clear structural depictions of reagents and chemical transformations have been supplied to permit the identification of other future applications.

Key features

  • Identifies next generation pharmaceuticals
  • Provides practical preparation methods for each active agent and derivatives
  • Documents the analytical characterization and biological testing results of active agents

Readership

For academic, government, and industrial researchers interested in organic chemistry, medicinal chemistry, natural products, pharmaceuticals, pharmacology and structure-property relationships.

Table of contents

Acquired Immune Deficiency Syndrome

Addiction Disorders

Alzheimer's Disease

Analgesics

Antibacterial Agents

Anti-inflammatory Agents

Autoimmune Disorders

Cardiovascular Disorders

Diabetes

Diagnostics

Epilepsy

Gastrointestional Disorders

Hepatitis C

Hormonal Disorders

Immunosuppressants

Improved Synthetic Methods

Incontinence

Irritable Bowel Syndrome

Osteoporosis

Malaria

Migraine Headaches

Obesity

Proliferative Disorders

Skin Disorders

Sleep Disorders

Thyroid Disorders

Tinnitus

Product details

  • Edition: 1
  • Latest edition
  • Published: June 11, 2007
  • Language: English

About the author

TD

Thomas F. DeRosa

Dr. DeRosa has a Ph.D. in Organic/Polymer Chemistry from the Polytechnic Institute of New York. He is the author of multiple books on Chemistry including Next Generation of International Chemical Additives: A Critical Review of Current US Patents (Elsevier, 2012, 9780444537881), Significant Pharmaceuticals Reported in US Patents (Elsevier Science, 2007, 9780080480916), and Advances in Synthetic Organic Chemistry and Methods Reported in US Patents (Elsevier Science, 2006, 9780080455631), has published 14 peer-reviewed papers and has been issued 47 US Patents associated with chemical additives.
Affiliations and expertise
Southbury, Connecticut, USA

View book on ScienceDirect

Read Significant Pharmaceuticals Reported in US Patents on ScienceDirect